Tag Archives: rhenium cluster compound

New formulation and activity of rhenium-platinum antitumor system

N. I. Shtemenko1,2*, D. E. Kytova1, O. V. Berzenina1,
O. I. Hrabovska1,3, A. V. Shtemenko1

1Ukrainian State University of Chemical Technology, Dnipro, Ukraine;
2Oles Honchar Dnipro National University, Ukraine;
3SI “Institute of Gastroenterology of the National Academy of Medical Sciences of Ukraine”, Dnipro, Ukraine;
*e-mail: n.shtemenko@ukr.net

Received: 16 November 2021; Revised: 10 January 2022; Accepted: 29 September 2022; Available on-line: October 2022

Two-component Rhenium-Platinum system (Re-Pt system) is based on administration of a cluster dirhenium(III) compound and cisplatin to tumor bearing animals followed by a significant antitumor effect and decreased toxic effect of cisplatin on normal cells. The aim of this work was to obtain solid lipid nanoparticles (SLN) from surface lipids (waxes) of Chelidonium majus L. (Papaveraceae) leaves and to estimate whether capsulation of dirhenium(III) as a component of the Re-Pt system into SLN will affect its antitumor activity and red blood cells (RBC) morphology in a rat model of Guerin’s carcinoma growth. Fourier-transform infrared spectroscopy, gas-liquid chromatography, microscopy, light scattering were used in the research. Solid lipid nanoparticles were obtained, characterized, loaded with cluster dirhenium(III) and being introduced together with cisplatin to rats with Guerin’s carcinoma resulted in RBC morphology preservation and a significant decrease in tumor weight. It was concluded that the lipid coating of the rhenium cluster compound did not reduce the antitumor effect of the Re-Pt system and protected RBC from toxic cisplatin influence­. A new formulation of the Re-Pt system is proposed.